The telehealth company is making a bold pivot that's driving growth, but the stock's recent slide has investors wondering if the price of admission is still too high.
Hims & Hers Health (HIMS) is in the middle of a major strategic shift, moving aggressively into branded weight-loss drugs and expanding its global reach through acquisitions like Eucalyptus. On its latest earnings call, management touted the early results of this pivot, noting the company is "on track to add north of 100,000 new subscribers per month" in its weight-loss business alone. Yet, despite this apparent momentum, the stock has been hit hard, falling about 35% from its recent high. That leaves you with a tough question: Is this pullback a genuine opportunity to own a growing business, or is it a trap?
To get a sense of what could happen next, it helps to look back. How has buying this stock after a steep drop worked out in the past?
HIMS: Historical Performance After a 30% Drop
The Track Record For Buying Hims & Hers Health On Weakness
#drop #recent #high
Hims & Hers Health (HIMS) is in the middle of a major strategic shift, moving aggressively into branded weight-loss drugs and expanding its global reach through acquisitions like Eucalyptus. On its latest earnings call, management touted the early results of this pivot, noting the company is "on track to add north of 100,000 new subscribers per month" in its weight-loss business alone. Yet, despite this apparent momentum, the stock has been hit hard, falling about 35% from its recent high. That leaves you with a tough question: Is this pullback a genuine opportunity to own a growing business, or is it a trap?
To get a sense of what could happen next, it helps to look back. How has buying this stock after a steep drop worked out in the past?
HIMS: Historical Performance After a 30% Drop
The Track Record For Buying Hims & Hers Health On Weakness
#drop #recent #high
3 months ago
